API
< Back to all clusters
[HEALTH] · South Korea · 3 sources

started · updated

Hyundai Bioscience receives approval for prostate cancer drug use

Hyundai Bioscience has obtained approval from the Ministry of Food and Drug Safety (MFDS) for the compassionate use of its anticancer drug candidate, Penetrium (CP-PCA07), for a patient in a Phase 1 clinical trial.

The patient, who suffers from metastatic castration-resistant prostate cancer (mCRPC), had completed a planned 12-week administration period. The approval allows for an additional six months of use in combination with the standard treatment, Enzalutamide, for patients who may find cytotoxic chemotherapy difficult to undergo.

Penetrium is an oral drug candidate based on niclosamide, designed to overcome “pseudo-resistance” caused by the tumor microenvironment. Hyundai Bioscience plans to provide a 180-day supply of the drug free of charge to the patient and will collaborate with medical staff to monitor safety and clinical efficacy.

Entities

Enzalutamide · Hyundai Bioscience · Ministry of Food and Drug Safety · Penetrium · Seoul National University Hospital